Jeeban P Das1, Hebert A Vargas1,2, Soleen Ghafoor1,2, Alvin C Goh3, Gary A Ulaner4,5. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Radiology, Weill Cornell Medical College, New York, New York. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; and. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York gary.ulaner@hoag.org. 5. Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, California.
Abstract
Our objective was to evaluate the impact of 18F-FDG PET CT on the management of urachal adenocarcinoma (UrC-ADC). Methods: A retrospective analysis of patients with UrC-ADC from 2001 to 2019 at Memorial Sloan Kettering was performed. Mayo stage before 18F-FDG PET/CT, rate of detection of the primary malignancy and metastases on 18F-FDG PET/CT, Mayo stage after 18F-FDG PET/CT, and change in patient management were determined. Results: Of 21 patients with UrC-ADC before 18F-FDG PET/CT, Mayo staging was I/II in 8, III in 3, and IV in 10. 18F-FDG PET/CT detected previously unidentified metastases in 8 (38%) of 21 patients, resulting in upstaging of disease in 3 (14%) patients and a change in treatment in 4 (19%) patients. Conclusion: 18F-FDG PET/CT has clinical utility in patients with UrC-ADC by identifying metastatic disease not appreciated on anatomic imaging, leading to changes in staging and patient management.
Our objective was to evaluate the impact of 18F-FDG PET CT on the management of urachal adenocarcinoma (UrC-ADC). Methods: A retrospective analysis of patients with UrC-ADC from 2001 to 2019 at Memorial Sloan Kettering was performed. Mayo stage before 18F-FDG PET/CT, rate of detection of the primary malignancy and metastases on 18F-FDG PET/CT, Mayo stage after 18F-FDG PET/CT, and change in patient management were determined. Results: Of 21 patients with UrC-ADC before 18F-FDG PET/CT, Mayo staging was I/II in 8, III in 3, and IV in 10. 18F-FDG PET/CT detected previously unidentified metastases in 8 (38%) of 21 patients, resulting in upstaging of disease in 3 (14%) patients and a change in treatment in 4 (19%) patients. Conclusion: 18F-FDG PET/CT has clinical utility in patients with UrC-ADC by identifying metastatic disease not appreciated on anatomic imaging, leading to changes in staging and patient management.
Authors: Carolina Parada Villavicencio; Sharon Z Adam; Paul Nikolaidis; Vahid Yaghmai; Frank H Miller Journal: Radiographics Date: 2016 Nov-Dec Impact factor: 5.333
Authors: Bruce E Hillner; Barry A Siegel; Dawei Liu; Anthony F Shields; Ilana F Gareen; Lucy Hanna; Sharon Hartson Stine; R Edward Coleman Journal: J Clin Oncol Date: 2008-03-24 Impact factor: 44.544
Authors: Julian R Molina; J Fernando Quevedo; Alfred F Furth; Ronald L Richardson; Horst Zincke; Patrick A Burch Journal: Cancer Date: 2007-12-01 Impact factor: 6.860
Authors: Donald A Podoloff; Douglas W Ball; Edgar Ben-Josef; Al B Benson; Steven J Cohen; R Edward Coleman; Dominique Delbeke; Maria Ho; David H Ilson; Gregory P Kalemkerian; Richard J Lee; Jay S Loeffler; Homer A Macapinlac; Robert J Morgan; Barry Alan Siegel; Seema Singhal; Douglas S Tyler; Richard J Wong Journal: J Natl Compr Canc Netw Date: 2009-06 Impact factor: 11.908